Systemic adjuvant chemotherapy for advanced malignant ocular medulloepithelioma

• Published in: Eye (London) 2023-04, Vol.37 (5), p.947-952
• Main Authors: Sheriff, Ibrahim H. N., Karaa, Esin K., Chowdhury, Tanzina, Scheimberg, Irene, Duncan, Catriona, Reddy, M. Ashwin, Sagoo, Mandeep S.
• Format: Article
• Language: English
• Subjects: 631/67/1059/99; 692/699/67/1484; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carboplatin; Carboplatin - therapeutic use; Chemotherapy; Chemotherapy, Adjuvant; Child; Child, Preschool; Enucleation; Epithelium; Etoposide; Etoposide - therapeutic use; Eye Enucleation; Humans; Laboratory Medicine; Male; Medicine; Medicine & Public Health; Metastases; Metastasis; Neuroectodermal Tumors, Primitive - drug therapy; Neuroectodermal Tumors, Primitive - pathology; Neuroectodermal Tumors, Primitive - surgery; Ophthalmology; Pharmaceutical Sciences/Technology; Retrospective Studies; Surgery; Surgical Oncology; Tumors; Vincristine; Vincristine - therapeutic use
• ISSN: 0950-222X; 1476-5454
• DOI: 10.1038/s41433-022-01936-4

Background Ocular medulloepithelioma (diktyoma) is a rare and potentially malignant paediatric tumour of the non-pigmented ciliary epithelium. Adjuvant chemotherapy can be given in advanced cases, but the indications and regimens remain to be defined. The aim was to identify whether adjuvant chemotherapy offers treatment benefit in advanced ocular medulloepithelioma. Methods This was a retrospective case series of subjects referred to a single specialist ocular oncology centre for advanced ocular medulloepithelioma subsequently treated with enucleation, including those needing adjuvant systemic vincristine, etoposide and carboplatin. A case-note review was performed for included subjects meeting referral criteria. The outcomes were histopathology characteristics, recurrence, metastases and survival. Results Between March 2010 and June 2017, four male patients (mean age 31 months) underwent enucleation for ocular medulloepithelioma. Adjuvant chemotherapy was commenced in 3 patients (75%) due to malignant histopathological features. With a mean follow-up time of 81.5 months (median 71 months, range 49–135 months) none of the patients have had recurrence, metastases or death from the tumour. Conclusions This series is unique in reporting the management of advanced malignant ocular medulloepithelioma with adjuvant systemic vincristine, etoposide and carboplatin for advanced tumours with malignant features. This regimen appears to be safe and may be effective in preventing metastatic spread.